Freenome Launches Multi-Cancer Detection Study Pairing Multiomics with Real-World Data
Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the company’s latest study of its multiomics platform, in combination with real-world data to detect multiple cancers.
Source: hitconsultant.net